Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response—a scoping review
Age-related macular degeneration is a major cause of blindness, and the development of anti-vascular endothelial growth factor (VEGF) intravitreal treatments has revolutionised the management of the disease. At the same time, new challenges and unmet needs arose due to the limitations of the current...
Saved in:
Main Authors: | Nikolaos Dervenis, Eleftherios Agorogiannis, Panagiotis Dervenis |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-05-01
|
Series: | BMJ Open Ophthalmology |
Online Access: | https://bmjophth.bmj.com/content/9/1/e001516.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
OCT Biomarkers in Neovascular Age-Related Macular Degeneration: A Narrative Review
by: Cristian Metrangolo, et al.
Published: (2021-01-01) -
Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
by: Ilias Zampros, et al.
Published: (2012-01-01) -
The first experience with brolucizumab for neovascular age-related macular degeneration
by: A.N. Kulikov, et al.
Published: (2022-05-01) -
Treatment for neovascular age-related macular degeneration: reasonable expectations of physicians and patients
by: A.B. Durasov
Published: (2021-09-01) -
Predictive value of different baseline optical coherence tomography biomarkers for visual acuity changes in neovascular age-related macular degeneration
by: Hamid Riazi-Esfahani, et al.
Published: (2025-02-01)